Jun Ma

Jun Ma

Auto-generated profile, based on publicly available information

Jun Ma

Department of Orthopaedics, Jiaxing Key Laboratory of Basic Research and Clinical Translation on Orthopedic Biomaterials, The Second Affiliated Hospital of Jiaxing University (Sports Hospital of Jiaxing), 1518 North Huancheng Road, Jiaxing, 314000, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HYHan Yu
Han Yu
PRPeng Ren
Peng Ren
XPXueKang Pan
XueKang Pan
XZXinyu Zhang
Xinyu Zhang
JMJun Ma
Jun Ma
GCGang Chen
Gang Chen
Treatment of osteoarthritis (OA) remains a significant clinical challenge. Itaconate (IA), an emerging regulator of intracellular inflammation and oxidative stress, may potentially be harnessed to treat OA. However, the short joint residence time, inefficient drug delivery, and cell-impermeable property of IA can seriously hamper the clinical translation. Herein, IA-encapsulated zeolitic imidazolate framework-8 (IA-ZIF-8) nanoparticles were self-assembled by zinc ions, 2-methylimidazole, and IA to render them pH-responsive. Subsequently, IA-ZIF-8 nanoparticles were firmly immobilized in hydrogel microspheres via one-step microfluidic technology. It was demonstrated in vitro experiments that IA-ZIF-8-loaded hydrogel microspheres (IA-ZIF-8@HMs) exhibited good anti-inflammatory and anti-oxidative stress effects by releasing pH-responsive nanoparticles into chondrocytes. Importantly, compared with IA-ZIF-8, IA-ZIF-8@HMs showed better performance in the treatment of OA due to their superior performance in sustained release. Thus, such hydrogel microspheres not only hold enormous potential for OA therapy, but also provide a novel avenue for cell-impermeable drugs by constructing appropriate drug delivery systems.

3 April 2026 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
JMJun Ma
Jun Ma
CCChen Chen
Chen Chen
HJHao Jiang
Hao Jiang
MXMengran Xi
Mengran Xi
WLWei Luo
Wei Luo
PYPatrick Shu-Hang YUNG
Patrick Shu-Hang YUNG
Sarcopenia and osteoarthritis are two common musculoskeletal disorders that often coexist, posing significant challenges in clinical management. These conditions share underlying mechanisms such as chronic inflammation, metabolic dysfunction, and biomechanical stress, which accelerate musculoskeletal degeneration. Sarcopenia, characterized by muscle loss and weakness, and osteoarthritis, marked by cartilage degradation and joint dysfunction, frequently overlap, leading to increased disability and reduced quality of life. The presence of both conditions creates a detrimental cycle where muscle weakness exacerbates joint pain, and joint dysfunction further weakens muscles. This comorbidity complicates treatment, requiring integrated strategies that address both muscle and joint pathology. Advances in personalized therapies, driven by multi-omics technologies, are crucial in targeting these interconnected conditions more effectively. Precision medicine, using genetic, metabolic, and physiological data, can help tailor treatments and improve patient outcomes. Furthermore, the integration of adaptive interventions, digital twin models, and real-time feedback systems will play key roles in refining individualized treatment plans. Multi-omics integration and real-world evidence are also transforming how clinical trials are designed and how we assess disease progression, moving away from structural markers to functional and patient-centered outcomes. Effective interventions must involve early detection, personalized approaches, and interdisciplinary care, aiming to break the cycle of degeneration and improve patients' functional independence and quality of life. This review identifies the biomechanical, metabolic, and epigenetic "vicious cycles" that drive the comorbidity of sarcopenia and osteoarthritis. By integrating multi-omics data, digital twin modeling, and real-time biomechanical feedback, this work provides a framework for clinical precision medicine. The clinical significance lies in identifying a "mechanical window of opportunity" for early intervention-using personalized exercise and nutritional strategies to restore joint homeostasis and prevent irreversible functional decline.